Recursion Pharmaceuticals wants to disrupt drug development. It's leaning on new ... but it's still early in the game. Still, innovative businesses also tend to be risky investments.

though that version of the tool would likely use publicly available datasets and models rather than Recursion’s own. In terms of future development, Gibson says the company is also looking for ...